SYNBIOTIC SE |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.2 EUR | -3.97% |
|
-3.16% | +207.69% |
| 23/04 | SynBiotic Boosts CBD Business with Ilesol Pharmaceuticals Takeover | MT |
| 23/04 | SynBiotic SE acquired Ilesol Pharmaceuticals d.o.o. za proizvodnju i usluge. | CI |
Business Summary
Number of employees: 104
Sales per Business
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Cannabinoids, Dietary Supplements and Cosmetic Products
100.0
%
| 9 | 100.0 % | 8 | 100.0 % | -5.58% |
Sales per region
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Germany
100.0
%
| 8 | 93.0 % | 8 | 100.0 % | +1.47% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Kruse
CEO | Chief Executive Officer | - | 21/23/21 |
Rebecca Kruse
DFI | Director of Finance/CFO | - | 01/23/01 |
Thomas Haffner
CTO | Chief Tech/Sci/R&D Officer | - | - |
Lars Müller
PRN | Corporate Officer/Principal | - | 10/20/10 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Frank Otto
BRD | Director/Board Member | - | - |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 4,677,379 | 4,677,379 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Sector
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.2
EUR
Average target price
15.2
EUR
Spread / Average Target
+65.22%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +207.69% | 46.39M | |
| +112.55% | 2.08B | |
| +131.75% | 77.54M | |
| +203.85% | 50.39M |
- Stock Market
- Equities
- SBX Stock
- Company SynBiotic SE